Radiological assessment of immunotherapy effects and immune checkpoint‐related pneumonitis for lung cancer
Authors:
Open Access
- 31 July 2023
- journal article
- review article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (5)
Abstract
Immune checkpoint inhibitors (ICIs) therapy have revolutionized advanced lung cancer care. Interestingly, the host responses for patients received ICIs therapy are distinguishing from those with cytotoxic drugs, showing potential initial transient worsening of disease burden, pseudoprogression and delayed time to treatment response. Thus, a new imaging criterion to evaluate the response for immunotherapy should be developed. ICIs treatment is associated with unique adverse events, including potential life‐threatening immune checkpoint inhibitor‐related pneumonitis (ICI‐pneumonitis) if treated patients are not managed promptly. Currently, the diagnosis and clinical management of ICI‐pneumonitis remain challenging. As the clinical manifestation is often nonspecific, computed tomography (CT) scan and X‐ray films play important roles in diagnosis and triage. This article reviews the complications of immunotherapy in lung cancer and illustrates various radiologic patterns of ICI‐pneumonitis. Additionally, it is tried to differentiate ICI‐pneumonitis from other pulmonary pathologies common to lung cancer such as radiation pneumonitis, bacterial pneumonia and coronavirus disease of 2019 (COVID‐19) infection in recent months. Maybe it is challenging to distinguish radiologically but clinical presentation may help.Keywords
This publication has 94 references indexed in Scilit:
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperAnnals of Oncology, 2015
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisBMC Medicine, 2015
- Immune Checkpoint Blockade in Cancer TherapyJournal of Clinical Oncology, 2015
- Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancerLung Cancer, 2015
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody TherapyAmerican Journal of Roentgenology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungusHistoplasma capsulatumProceedings of the National Academy of Sciences, 2008